Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene er større end risiciene ved Tygacil til behandling af komplicerede infektioner i huden og det underliggende væv og til behandling af komplicerede infektioner i bughulen.
The Committee for Medicinal Products for Human Use (CHMP) decided that Tygacil’ s benefits are greater than its risks for the treatment of complicated skin and soft tissue infections and for the treatment of complicated intra-abdominal infections.